Norwegian Cohort Finds 49% of Childhood Cancer Survivors Report Clinical Depression Symptoms in Adulthood

Hjort and Franzén recruited survivors from Oslo University Hospital and St. Olav’s, administering validated scales for depression, anxiety, fatigue, and cognitive function. The cross-sectional design captured self-reported symptoms but lacked structured clinical interviews or medical-record verification of treatment exposures. Nearly half the sample met thresholds for clinically relevant distress, exceeding the 7-10% lifetime depression prevalence in Norwegian adults.

Developmental disruption during peak brain and social maturation likely compounds direct neurotoxic effects of intrathecal chemotherapy. Earlier cohorts showed lower mental-health estimates partly because shorter survival windows and different treatment eras limited follow-up. The current findings align with Dutch and US Childhood Cancer Survivor Study data indicating persistent internalizing disorders, yet add granularity on fatigue-cognition overlap often missed in shorter studies.

Routine survivorship care in Norway still prioritizes cardiac and endocrine screening; mental-health pathways remain ad-hoc. Next steps require prospective cohorts linking cumulative chemotherapy dose and hospitalization duration to symptom trajectories, plus RCTs testing stepped-care CBT or digital interventions initiated in late adolescence.